RxDoctor Payments Data

Daniel Woodford, MD

Internal Medicine · Bowling Green, VANPI 1790761302

Payments from drug & device makers

$1,069in general payments, 2019–2025

Across 55 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$182
  • Abbott$176
  • Edwards Lifesciences$124
  • AbbVie$115
  • Pfizer$64
  • Otsuka America Pharmaceutical, Inc.$56
  • plus $353 from 14 others

What the payments were for

  • Food & beverage$1,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,069 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$118,416
Medicare patients
371
Services billed
1,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$104,526
OzempicSemaglutide76$97,196
JardianceEmpagliflozin54$61,403
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$45,606
JanuviaSitagliptin Phosphate57$39,348
MounjaroTirzepatide23$32,108
TrulicityDulaglutide28$29,680
XareltoRivaroxaban11$16,974
TradjentaLinagliptin14$12,982
Aimovig AutoinjectorErenumab-Aooe12$10,172
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$9,627
Tiotropium Bromide17$7,194
Breo ElliptaFluticasone/Vilanterol16$6,885
JanumetSitagliptin Phos/Metformin Hcl13$6,517
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$104,526115 claims
Novo NordiskOzempic$182$97,19676 claims
Boehringer IngelheimJardiance, Tradjenta$19$74,38568 claims
Lilly USA, LLCMounjaro, Trulicity$13$61,78851 claims
GSKTrelegy Ellipta, Breo Ellipta$51$52,49269 claims
Johnson & JohnsonXarelto$28$16,97411 claims
AbbVieSynthroid$115$1,40740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Bowling Green

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →